Clinical

A significant subset of patients continues to receive chemotherapy monotherapy despite the availability of newer approaches, including programmed cell death protein-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors.

This subanalysis of data from the ELDERCARE-AF trial investigated the safety and effectiveness of a 15-mg daily dose of the factor Xa inhibitor among older patients who have atrial fibrillation (AFib).

A new review outlines what is known about cardiovascular disease (CVD) risk in patients with systemic lupus erythematosus (SLE) and how that might affect patient care.

Researchers studied data from 5 phase 1 studies that took place between 2012 and 2021, comprising 139 infusions among patients with B-cell acute lymphoblastic leukemia who received chimeric antigen receptor (CAR) T-cell treatment.

The pandemic has changed how care has delivered, but what professionals new to health care know about strategies used to connect with patients in a virtual setting, or the quality of the instruction they receive, is not known.

Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on key areas of HS comprehension and management that warrant further investigation in clinical research.

A study found cystatin C, renal resistance index, and urinary kidney injury molecule-1 were significantly associated with risk of diabetic kidney disease (DKD) in children and adolescents with type 1 diabetes (T1D).

Dr Oskouei explains the indications for adalimumab and the impact of their extrapolation, as well as differences among adalimumab products.

An expert authority explains the treatment selection process for a patient, as well as the different ways to administer PrEP.

Lynne H. Milgram, MD, MBA, CPE, iterates the importance of PrEP as an HIV prevention tactic and how walk away and fill rates are evaluated.

Medical experts discuss benefits of titrating therapies for management of ejection fraction pathologies.

Dr Januzzi analyzes preventive approaches for patients with pre-heart failure, including comorbidity considerations and preliminary testing.

David Rosmarin, MD, discusses the prevalence and incidence of vitiligo across a diverse patient population.

A panel of experts open a discussion surrounding vitiligo, including the definition and nature of the disease.

Edward Arrowsmith, MD, concludes with his thoughts on developing therapies and how they are implemented into clinical pathways for NSCLC treatment.

Dr Arrowsmith discusses the role immune checkpoint inhibitors play in NSCLC therapy, both as monotherapy and in combination therapy.

The FDA Wednesday approved betibeglogene autotemcel (Zynteglo), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Dr Feldman describes the populations that are most at risk of developing CKD.

Jeffrey Feldman, MD, and Rajiv Agarwal, MD, MS, provide an overview of chronic kidney disease (CKD) and its prevalence.

Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also found differences between anti-IL-17A inhibitors.

While noting that providers and their patients should be aware of the potential risk, the researchers underscored that the risk of new-onset psoriasis due to tumor necrosis factor-α inhibitor (TNFi) treatment appears to be rare and that strategies do not need to change for patients with immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD) and/or rheumatoid arthritis (RA).

The case describes hemophagocytic lymphohistiocytosis (HLH), which occurred in a young boy in Italy with spinal muscular atrophy, who was treated with onasemnogene abeparvovec.

Dr Palella Jr highlights how clinicians support patient access to PrEP and what his experiences have shown him about patient adherence with the available oral therapies.

Carl Schmid, an HIV/PrEP advocate, provides an overview of PrEP therapy; Frank J. Palella Jr, MD, a clinician focused on HIV and infectious disease, delves into the diagnostic process.